References
- Slatopolsky E., Brown A., Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int. 1999; 56: S14–S19
- Llach F., Forero FV. Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspect. Am. J. Kidney. Dis. 2001; 38(5)S20–S33
- Llach F. Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited. Am. J. Kidney. Dis. 1999; 25(5)663–679
- Slatopolsky E., Bricker N.S. The role of phosphorous restriction in the prevention of secondary hyperparathyroidism in renal disease. Kidney Int. 1973; 4: 141–148
- Sakhaee K. Is there an optimal parathyroid hormone level in end stage renal failure, the lower the better. Curr. Opin. Nephrol. Hypertens. 2001; 10(3)421–427
- Drüeke T.B. Medical management of secondary hyperparathyroidism in uremia. Am. J. Med. Sci. 1999; 317(6)383–390
- Salem M.M. Hyperparathyroidism in the hemodialysis population: a survey of 612 patients. Am. J. Kidney. Dis. 1997; 29(6)862–865
- Billa V., Zhong A., Bargman J., Vas S., Wong P.Y., Oreopoulos D.G. High prevalence of hyperparathyroidism among peritoneal dialysis patients: a review of 176 patients. Perit. Dial. Int. 2000; 20: 315–321
- Gupta A., Kallenbach L.R., Zasuwa G., Divine G.W. Race is a major determinant of secondary hyperparathyroidism in uremic patients. J. Am. Soc. Nephrol. 2000; 11: 330–334
- Stehman-Breen C.O., Sherrard D., Walker A., Sadler R., Alem A., Lindberg J. Racial difference in bone mineral density and bone loss among end-stage renal disease patients. Am. J. Kidney Dis. 1999; 33(5)941–946
- Qi Q., Monier-Faugere M., Geng Z., Malluche H.H. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am. J. Kidney Dis. 1995; 26(4)622–631
- Hutchison A.J., Whitehouse R.W., Boulton H.F., Adams J.E., Mawer E.B., Freemont T.J., Gokal R. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int. 1993; 44: 1071–1077
- Neff M.S., Eiser A.R., Slifkin R.F., Baum M., Baez A., Gupta S., Amarga E. Patients surviving 10 years of hemodialysis. Am. J. Med. 1983; 74: 996–1004
- Chertow G.M., Plone M., Dillon M.A., Burke S.K., Slatopolsky E. Hyperparathyroidism and dialysis vintage. Clin. Nephrol. 2000; 54(4)295–300
- Tokuyama K., Iseki K., Yoshi S., Yoshihara K., Nishime K., Uehara H., Tozawa M., Wake T., Arakaki M., Fukiyama K. An epidemiologic analysis of parathyroidectomy in chronic dialysis patients. Jpn. J. Nephrol. 1996; 38: 309–313
- Vincenti F., Hattner R., Amend W.J., Feduska N., Duca R.M., Salvatierra O. Decreased secondary hyperparathyroidism in diabetic patients receiving hemodialysis. JAMA 1981; 245(9)930–933
- Kikunami K., Nishizawa Y., Tabata T., Nakatsuka K., Matsushita Y., Inoue T., Miki T., Morii H. Changes in parathyroid hormone in diabetic patients on long-term hemodialysis. Nephron. 1990; 54: 318–321
- Andress D.L., Kopp J.B., Maloney N.A., Coburn J.W., Sherrard K.J. Early deposition of aluminum in bone in diabetic patients on hemodialysis. N. Eng. J. Med. 1987; 316: 292–296
- Cundy T.F., Humphreys S., Watkins P.J., Parsons V. Hyperparathyroid bone disease in diabetic renal failure. Diabetes Res. 1990; 14: 191–196
- Weinstein R.S., Bell N.H. Diminished rates of bone formation in normal black adults. N. Eng. J. Med. 1988; 319: 1698–1701
- Owda A., Mousa D., Abdalla H.A., Hawas F.A., Al-Harbi W., Fedail H., Al-Shoail G., Al-Sulaiman M.H., Al-Khader A.A. Long-term intravenous calcitriol in secondary hyperparathyroidism: the role of Technetium-99m-MIBI scintigraphy in predicting the response to treatment. Renal. Fail. 2002; 24(2)165–173
- Fukagawa M., Kitaoka M., Yi H., Fukuda N., Matsumoto T., Ogata E., Kurokawa K. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron. 1994; 68: 221–228
- Katoh N., Nakayama M., Shigematsu T., Yamamoto H., Sano K., Saito I., Nakano H., Kasai K., Kubo H., Sakai S., Kawaguchi Y., Hosoya T. Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidism. Am. J. Kidney. Dis. 2000; 35(3)465–468